Margaret Chisolm, MD, shares a model of flourishing that moves beyond symptomatic treatment and helps patients find meaningful lives even when their medications do not work.

Each year in the US, there are about 1.04 million divorces, affecting about 800,000 children, and it may not be the divorce itself that is hard on children, but how the divorce is handled. How can we navigate the complexities of treating a child with divorced or separated parents?

Can we treat depression by targeting inflammation? Do SSRIs for post-stroke depression increase the risk of second intracranial hemorrhage? And how effective is the new combination treatment, olanzapine/samidorphan, for mitigating antipsychotic-induced weight gain? We will answer these questions in this Hospital Psychiatry Research Update Extravaganza!

Omega-3 fatty acids do treat depression, but not with the formulations that are commonly found on the shelves. Here we point you in the right direction, and give a winding origin story of these essential fatty acids.

Do antipsychotics have neurotoxic effects in youth? In this episode, we’ll be banging the drum of caution about antipsychotic use in children and adolescents. 

Lybalvi combines olanzapine with the opioid blocker samidorphan in hopes of curbing the weight gain on that antipsychotic. Here, we look at how well it works.

Methamphetamine is the second most abused drug in the U.S. We bring you up to speed on the basics in this episode.

The pharmaceutical industry created 3 myths around opioids: “Pain as the fifth vital sign,” the less-than-1% rate of addiction, and the diagnosis of pseudoaddiction. Inside, we look at what is true and what is exaggeration in these claims.